Trial Profile
Subcutaneous continuous infusion of interferon alfa-2b and ribavirin in hepatitis C genotype 1 nonresponders
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 07 Aug 2022
Price :
$35
*
At a glance
- Drugs Interferon alpha-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacogenomic
- Acronyms SCIN-C
- 13 Dec 2011 Results published in Antiviral Therapy.
- 10 Mar 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
- 10 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.